company background image
ABNX

ABIONYX Pharma ENXTPA:ABNX Stock Report

Last Price

€1.92

Market Cap

€53.1m

7D

7.8%

1Y

82.0%

Updated

04 Aug, 2022

Data

Company Financials +
ABNX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ABNX Stock Overview

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases.

ABIONYX Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ABIONYX Pharma
Historical stock prices
Current Share Price€1.92
52 Week High€3.57
52 Week Low€0.90
Beta0.18
1 Month Change27.02%
3 Month Change1.16%
1 Year Change81.97%
3 Year Change536.15%
5 Year Change8.98%
Change since IPO-84.44%

Recent News & Updates

Jan 27
Will ABIONYX Pharma (EPA:ABNX) Spend Its Cash Wisely?

Will ABIONYX Pharma (EPA:ABNX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

ABNXFR BiotechsFR Market
7D7.8%1.3%2.9%
1Y82.0%-41.1%-5.6%

Return vs Industry: ABNX exceeded the French Biotechs industry which returned -41.6% over the past year.

Return vs Market: ABNX exceeded the French Market which returned -5.8% over the past year.

Price Volatility

Is ABNX's price volatile compared to industry and market?
ABNX volatility
ABNX Average Weekly Movement9.5%
Biotechs Industry Average Movement6.7%
Market Average Movement5.1%
10% most volatile stocks in FR Market9.1%
10% least volatile stocks in FR Market2.9%

Stable Share Price: ABNX is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ABNX's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
200562Cyrille Tupinhttps://abionyx.com

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France.

ABIONYX Pharma Fundamentals Summary

How do ABIONYX Pharma's earnings and revenue compare to its market cap?
ABNX fundamental statistics
Market Cap€53.13m
Earnings (TTM)-€5.82m
Revenue (TTM)€675.00k

78.7x

P/S Ratio

-9.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABNX income statement (TTM)
Revenue€675.00k
Cost of Revenue€416.00k
Gross Profit€259.00k
Other Expenses€6.08m
Earnings-€5.82m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 29, 2022

Earnings per share (EPS)-0.21
Gross Margin38.37%
Net Profit Margin-862.52%
Debt/Equity Ratio21.6%

How did ABNX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ABNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABNX?

Other financial metrics that can be useful for relative valuation.

ABNX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue74.3x
Enterprise Value/EBITDA-8.5x
PEG Ration/a

Price to Book Ratio vs Peers

How does ABNX's PB Ratio compare to its peers?

ABNX PB Ratio vs Peers
The above table shows the PB ratio for ABNX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.7x
ALVAL Valbiotis
4.3x100.7%€60.8m
ALSEN Sensorion
0.8x-24.2%€34.2m
ALNOV Novacyt
0.6xn/a€98.0m
COX Nicox
1.1x23.5%€79.5m
ABNX ABIONYX Pharma
5x-26.8%€53.1m

Price-To-Book vs Peers: ABNX is expensive based on its Price-To-Book Ratio (5x) compared to the peer average (1.7x).


Price to Earnings Ratio vs Industry

How does ABNX's PE Ratio compare vs other companies in the FR Biotechs Industry?

Price-To-Book vs Industry: ABNX is expensive based on its Price-To-Book Ratio (5x) compared to the French Biotechs industry average (2.5x)


Price to Book Ratio vs Fair Ratio

What is ABNX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABNX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ABNX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ABNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ABNX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ABNX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is ABIONYX Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-26.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABNX's revenue (63.6% per year) is forecast to grow faster than the French market (5.3% per year).

High Growth Revenue: ABNX's revenue (63.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ABNX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has ABIONYX Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


45.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ABNX is currently unprofitable.

Growing Profit Margin: ABNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ABNX is unprofitable, but has reduced losses over the past 5 years at a rate of 45.4% per year.

Accelerating Growth: Unable to compare ABNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.6%).


Return on Equity

High ROE: ABNX has a negative Return on Equity (-54.53%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is ABIONYX Pharma's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ABNX's short term assets (€13.0M) exceed its short term liabilities (€6.7M).

Long Term Liabilities: ABNX's short term assets (€13.0M) exceed its long term liabilities (€4.4M).


Debt to Equity History and Analysis

Debt Level: ABNX has more cash than its total debt.

Reducing Debt: ABNX's debt to equity ratio has reduced from 48.2% to 21.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABNX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ABNX has less than a year of cash runway if free cash flow continues to grow at historical rates of 32% each year.


Discover healthy companies

Dividend

What is ABIONYX Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABNX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ABNX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Cyrille Tupin (45 yo)

2.92yrs

Tenure

€4,641,579

Compensation

Sir Cyrille Tupin, CPA is Chief Executive Officer, General Manager and Director at ABIONYX Pharma SA since September 6, 2019. Mr. Tupin served as the Chief Financial and Administrative Officer at ABIONYX...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Cyrille's total compensation is reasonable compared to companies of similar size in the French market.

Compensation vs Earnings: Insufficient data to compare Cyrille's compensation with company performance.


Leadership Team

Experienced Management: ABNX's management team is considered experienced (3.6 years average tenure).


Board Members

Experienced Board: ABNX's board of directors are considered experienced (6.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.5%.


Top Shareholders

Company Information

ABIONYX Pharma SA's employee growth, exchange listings and data sources


Key Information

  • Name: ABIONYX Pharma SA
  • Ticker: ABNX
  • Exchange: ENXTPA
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €53.127m
  • Shares outstanding: 27.70m
  • Website: https://abionyx.com

Number of Employees


Location

  • ABIONYX Pharma SA
  • 33 43 av. Georges Pompidou Bât. D2
  • Balma
  • Midi-Pyrénées
  • 31130
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/04 00:00
End of Day Share Price2022/08/04 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.